Sign up to save your podcasts
Or
Share Early HR+ Disease SABCS 2025 Practice Changing/Informing Highlights: ALTTO, lidERA, NATALEE
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Early HR+ Disease SABCS 2025 Practice Changing/Informing Highlights: ALTTO, lidERA, NATALEE
In this episode of The Oncology Brothers, we were joined by Dr. Laura Huppert from UCLA to discuss the latest practice-changing findings from the SABCS 2025 conference, focusing on early-stage hormone receptor-positive breast cancer.
Join us as we dive into three key abstracts:
1. ALTTO Study: Discover the results comparing aromatase inhibitors to tamoxifen in triple-positive breast cancer and the implications for treatment strategies.
2. lidERA Study: Learn about the promising data on the oral selective estrogen receptor degrader (SERD) giredestrant, which shows significant improvement in invasive disease-free survival compared to standard endocrine therapy.
3. NATALEE Trial: Get insights into the five-year update on ribociclib in combination with aromatase inhibitors, highlighting its benefits across different patient subgroups (stages, nodal status).
We explored the evolving landscape of endocrine therapy, the importance of side effect profiles, and how these findings may influence clinical practice moving forward.
Don't miss this informative discussion that could reshape your approach to treating early-stage hormone receptor-positive breast cancer!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Subscribe to our channel for more updates on treatment algorithms, recent approvals, and conference highlights.
#SABCS2025 #BreastCancer #AdjuvantTherapy #Giredestrant #Ribociclib #AI #OncologyBrothers #HRpositiveBC
View all episodes
By Oncology Brothers
4.9
4242 ratings
In this episode of The Oncology Brothers, we were joined by Dr. Laura Huppert from UCLA to discuss the latest practice-changing findings from the SABCS 2025 conference, focusing on early-stage hormone receptor-positive breast cancer.
Join us as we dive into three key abstracts:
1. ALTTO Study: Discover the results comparing aromatase inhibitors to tamoxifen in triple-positive breast cancer and the implications for treatment strategies.
2. lidERA Study: Learn about the promising data on the oral selective estrogen receptor degrader (SERD) giredestrant, which shows significant improvement in invasive disease-free survival compared to standard endocrine therapy.
3. NATALEE Trial: Get insights into the five-year update on ribociclib in combination with aromatase inhibitors, highlighting its benefits across different patient subgroups (stages, nodal status).
We explored the evolving landscape of endocrine therapy, the importance of side effect profiles, and how these findings may influence clinical practice moving forward.
Don't miss this informative discussion that could reshape your approach to treating early-stage hormone receptor-positive breast cancer!
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Subscribe to our channel for more updates on treatment algorithms, recent approvals, and conference highlights.
#SABCS2025 #BreastCancer #AdjuvantTherapy #Giredestrant #Ribociclib #AI #OncologyBrothers #HRpositiveBC
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
58 Listeners
Pod Save America
87,276 Listeners
Core IM | Internal Medicine Podcast
1,145 Listeners
The ONS Podcast
206 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Lung Cancer Considered
26 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Oncology On The Go
4 Listeners
Blood Cancer Talks
51 Listeners
Two Onc Docs
192 Listeners
Oncology for the Inquisitive Mind
4 Listeners